Prognostic assessment for early breast cancer in the clinic is currently made from clinical and pathological parameters, which at present include three biomarkers: estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [1-3]. The gene discussed is ESR1; the disease is breast carcinoma.